A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

ClinicalTrials.gov ID: NCT04947579

Public ClinicalTrials.gov record NCT04947579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing Spondylitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.

Study identification

NCT ID: NCT04947579
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Celgene; Industry
Enrollment: 167 participants

Conditions and interventions

Conditions

Spondylitis, Ankylosing

Interventions

CC-99677 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 24, 2021
Primary completion: Feb 20, 2023
Completion: Feb 20, 2023
Last update posted: Apr 30, 2024

2021 – 2023

United States locations

U.S. sites: 16
U.S. states: 8
U.S. cities: 16

Facility	City	State	ZIP	Site status
Local Institution - 024	Flagstaff	Arizona	86001	—
Local Institution - 021	Gilbert	Arizona	58297	—
Local Institution - 022	Phoenix	Arizona	95037	—
Local Institution - 025	Tucson	Arizona	85704	—
Local Institution - 017	Tustin	California	92780	—
Local Institution - 026	Saint Clair Shores	Michigan	48081	—
Local Institution - 028	Cleveland	Ohio	44106	—
Local Institution - 004	Dayton	Ohio	45417	—
Local Institution - 009	Portland	Oregon	97239	—
Local Institution - 003	Duncansville	Pennsylvania	16635	—
Local Institution - 005	Jackson	Tennessee	38305	—
Local Institution - 002	Memphis	Tennessee	38119	—
Local Institution - 029	Austin	Texas	78731	—
Local Institution - 006	Colleyville	Texas	76034	—
Local Institution - 019	Fort Worth	Texas	76107	—
Local Institution - 008	Houston	Texas	77099	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04947579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2024 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04947579 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →